RxDoctor Payments Data

Leon Qiao, MD

Gastroenterology · Cedar Rapids, IANPI 1013992205

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 37.5% of the total. 2025 is the largest year on record at $289, more than ten times the $25 reported in 2019. That places this record below the midpoint for gastroenterology clinicians in IA, where the typical reported total is $554.

$789in general payments, 2019–2025

Across 42 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$296
  • Sanofi$132
  • Takeda Pharmaceuticals U.S.A., Inc.$79
  • Medtronic$72
  • Regeneron Healthcare Solutions, Inc.$66
  • Johnson & Johnson$54
  • plus $90 from 4 others

What the payments were for

  • Food & beverage$789100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$789 in reported general payments places this provider in the 50th percentile of 113 gastroenterology providers in Iowa.

See all gastroenterology providers in Iowa

Medicare billing

Part B allowed, 2024
$185,828
Medicare patients
810
Services billed
1,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab18$165,146
LinzessLinaclotide75$39,814
Mesalamine54$20,031
Dexlansoprazole DrDexlansoprazole40$11,905
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg510$10,944
Ursodiol18$6,200
Balsalazide Disodium34$6,193
Colesevelam Hcl43$4,582
Omeprazole383$4,331
Pantoprazole Sodium423$3,992
Entecavir29$1,625
Esomeprazole Magnesium48$1,358
Colestipol Hcl23$1,149
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg78$1,113
Azathioprine18$841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$296$39,81475 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 113 gastroenterology providers in Iowa.

Other gastroenterology in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →